Log in

NASDAQ:CRME - Cardiome Pharma Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume90,444 shs
Average Volume135,322 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRME
CUSIPN/A
Phone604-677-6905

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive CRME News and Ratings via Email

Sign-up to receive the latest news and ratings for CRME and its competitors with MarketBeat's FREE daily newsletter.


Cardiome Pharma (NASDAQ:CRME) Frequently Asked Questions

What is Cardiome Pharma's stock symbol?

Cardiome Pharma trades on the NASDAQ under the ticker symbol "CRME."

How were Cardiome Pharma's earnings last quarter?

Cardiome Pharma Co. (NASDAQ:CRME) issued its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. The biopharmaceutical company earned $6.54 million during the quarter, compared to the consensus estimate of $7.34 million. View Cardiome Pharma's Earnings History.

Has Cardiome Pharma been receiving favorable news coverage?

Media stories about CRME stock have trended somewhat negative on Tuesday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cardiome Pharma earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Cardiome Pharma.

Who are some of Cardiome Pharma's key competitors?

What other stocks do shareholders of Cardiome Pharma own?

Who are Cardiome Pharma's key executives?

Cardiome Pharma's management team includes the folowing people:
  • Dr. William L. Hunter, Pres, CEO & Director (Age 55)
  • Ms. Sheila M. Grant MBA, Chief Operating Officer
  • Mr. David D. McMasters, Gen. Counsel (Age 59)
  • Mr. Hugues Sachot, Chief Commercial Officer
  • Mr. Justin A. Renz, Chief Financial Officer (Age 46)

What is Cardiome Pharma's official website?

The official website for Cardiome Pharma is http://www.cardiome.com/.

How can I contact Cardiome Pharma?

Cardiome Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The biopharmaceutical company can be reached via phone at 604-677-6905 or via email at [email protected]


MarketBeat Community Rating for Cardiome Pharma (NASDAQ CRME)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  291 (Vote Outperform)
Underperform Votes:  262 (Vote Underperform)
Total Votes:  553
MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma and other stocks. Vote "Outperform" if you believe CRME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRME will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Featured Article: FinTech

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel